All In MedTech

Device Trial Radar · NCT07510919

CGM in Acute Ischemic Stroke

Continuous Glucose Monitoring for Enhanced Management of Hyperglycemia in Persons With Type 2 Diabetes Undergoing Endovascular Therapy for Acute Ischemic Stroke: a Randomized Controlled Trial.

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Apr 21, 2026

Primary completion

May 2028

Study completion Aug 2028

Sponsor

Lead sponsor
IsalaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medisch Spectrum Twente
First posted
Apr 6, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management. This study is designed as a multicenter, non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management in two stroke centers in the Netherlands. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose \>10 mmol/L) during the first 72 hours of hospitalization. Researchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients. Participants will: * Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management * Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization * Receive glucose management according to the assigned monitoring strategy, based on a standardized insulin correction scheme applied uniformly across all participating centers

Conditions

  • Acute Ischemic Stroke
  • Diabetes (DM)
  • Diabetes Type 2
  • Hyperglycemia
  • Stroke

Interventions

  • Continuous Glucose MonitoringDevice

    Continuous glucose monitoring using the FreeStyle Libre systems (Abbott Diabetes Care) to measure interstitial glucose levels through a subcutaneous sensor that continuously records glucose concentrations during hospitalization.

  • Point-of-Care TestingDiagnostic test

    Intermittent glucose monitoring using point-of-care finger-prick capillary blood glucose measurements according to the hospital glucose management protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time spent in hyperglycemia (>10 mmol/L)Time frame: During the first 72 hours of hospitalization

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Medisch Spectrum Twente

    Enschede, Netherlands · Not yet recruiting

  • Isala Zwolle

    Zwolle, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.